McKesson Corporation: enforcement record and regulatory exposure
McKesson Corporation scores 67 out of 100 on the RedFlag Index™ (October 2026), ranking #4 of ten tracked companies, with 3 documented cases of which 1 remain open.
Documented record
McKesson's opioid-related penalties total about $8.7 billion.
2022: McKesson agreed to pay up to $7.4 billion over 18 years in the national opioid distributor settlement.
2022: RxPak, a McKesson subsidiary, paid $1 million over more than 700 alleged controlled-substance record-keeping violations.
2017: McKesson paid $150 million, then a record for a distributor, for Controlled Substances Act violations. Controlled-substance shipments from four McKesson distribution centers were suspended.
McKesson's Colorado distribution center processed more than 1.6 million controlled-substance orders from 2008 to 2013 and reported only 16 as suspicious.
2008: McKesson paid $13.25 million for Controlled Substances Act violations.
RegulationWatch coverage
- Opioid Litigation
McKesson is paying up to $7.4 billion over opioid distribution, and admits nothing.
The largest distributor's share of the national settlement runs for 18 years. None of it goes to individual patients.
- Controlled Substances Act
McKesson reported 16 suspicious orders out of 1.6 million. The penalty was $150 million.
It was the company's second settlement for the same failure. The first, in 2008, had required it to build a monitoring system.
